SCHEMBL4921719

SCHEMBL4921719

FC(F)(F)Oc1ccc(-n2c(=S)[nH]c3cc(Cl)c(Cl)cc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.43
ALDH1A1 P00352 3/20 0.43
HPGD P15428 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
KCNH2 Q12809 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.39
POLB P06746 1/20 0.39
HRH3 Q9Y5N1 1/20 0.39
MAPK1 P28482 1/20 0.39
RECQL P46063 1/20 0.39
MEN1 O00255 2/20 0.36
KMT2A Q03164 2/20 0.36
ATM Q13315 1/20 0.36
TDP2 O95551 1/20 0.35
MPI P34949 1/20 0.34
APOBEC3G Q9HC16 1/20 0.34
ADRB3 P13945 1/20 0.34
TSPO P30536 1/20 0.34
GRM5 P41594 1/20 0.34
TMEM97 Q5BJF2 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4929848 0.86 PSMB8 (0.47) MAPTALDH1A1HPGDSMN1; SMN2KCNH2
SCHEMBL4931027 0.86 ALDH1A1 (0.45) MAPTALDH1A1HPGDSMN1; SMN2KCNH2
SCHEMBL4922308 0.84 L3MBTL1 (0.48) MAPTSMN1; SMN2L3MBTL1POLBHRH3
SCHEMBL14463406 0.78 HRH3 (0.43) MAPTALDH1A1HPGDSMN1; SMN2KCNH2
SCHEMBL4930651 0.75 PSMB8 (0.44) MAPTALDH1A1HPGDSMN1; SMN2KCNH2
SCHEMBL4929926 0.70 L3MBTL1 (0.44) MAPTKCNH2L3MBTL1POLBMAPK1
SCHEMBL14096388 0.70 PDE7A (0.66) MAPTALDH1A1HPGDSMN1; SMN2L3MBTL1
SCHEMBL4930459 0.70 L3MBTL1 (0.49) MAPTSMN1; SMN2L3MBTL1POLBMEN1
SCHEMBL4927637 0.70 HRH3 (0.47) MAPTALDH1A1HPGDSMN1; SMN2KCNH2
SCHEMBL4929661 0.68 HRH3 (0.43) MAPTSMN1; SMN2L3MBTL1HRH3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
US-20080021069-A1 Receptor Function Regulating Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-01-24 US disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed
EP-1810677-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2007-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080021069-A1 Receptor Function Regulating Agent GPR119, INSR, GPR65 MAPT 4574/4885ALDH1A1 1870/4885HPGD 1922/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.